A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Phase 1
45
about 3 years
18+
3 sites in AR, PA
What this study is about
This trial is testing a new treatment called BxC-I17e for people with moderate to severe atopic dermatitis. The goal is to see if it's safe, well-tolerated, and helps improve the condition.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BxC-I17e (primed iMSC derived Extracellular vesicles(EV))
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of treatment-emergent adverse events (TEAEs)
Secondary: Change and percent change in Pruritus Numerical Rating Scale (NRS), Incidence, severity and relationship of adverse events(AEs), Number of abnormalities and change from baseline in Vital signs
Dermatology